Liquidia Corporation (NasdaqCM: LQDA)
Health Care · Pharmaceuticals · US
$27.38
-2.28% today · +12.9% 1Y
Liquidia Corporation (NasdaqCM: LQDA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.45B and employs 216 people.
Over the last twelve months the share price has gained 12.9%, trading between 21.94 and 93.61.
Tweenvest scores Liquidia Corporation across four factors: quality 37/100, value 48/100, growth 100/100. Its strongest factor is growth.
LQDA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.45B
- Revenue (TTM)
- $450.91M
- P/E
- 18.53
- EPS
- 1.48
- Dividend yield
- —
- Beta (5Y)
- 0.61
- 52-week high
- $93.61
- 52-week low
- $21.94
- Avg volume (3M)
- —
- Shares outstanding
- 89.51M
- Employees
- 216
- Next earnings
- —
About Liquidia Corporation
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
- ISIN
- US53635D2027
- Founded
- 2004
- Listed since
- Jul 26, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| China Resources Double-Crane Pharmaceutical Co.,Ltd.SHSE: 600062 | $2.53B | CN¥16.44 | +1.23% |
| Supernus Pharmaceuticals, Inc.NasdaqGM: SUPN | $2.48B | $42.67 | +0.68% |
| Curaleaf Holdings, Inc.TSX: CURA | $2.47B | CA$13.31 | -6.33% |
| Almirall, S.A.BME: ALM | $2.46B | €10.08 | +0.20% |
| Aether Industries LimitedNSEI: AETHER | $2.40B | Rs1,748.10 | +4.68% |
| Jamjoom Pharmaceuticals Factory CompanySASE: 4015 | $2.39B | SR128.00 | +0.95% |
| Harmony Biosciences Holdings, Inc.NasdaqGM: HRMY | $2.35B | $40.28 | +1.72% |
| HUTCHMED (China) LimitedAIM: HCM | $2.33B | £2.03 | -2.87% |
Figures last refreshed Oct 11, 2026.